Senses Disorder TRIZ Cases

Aminopyrazole compounds selectively inhibit JAK1 to treat atopic dermatitis while avoiding anemia caused by EPO signaling interference.

Modified sFlt1 gene vectors express anti-angiogenic proteins to neutralize excess VEGF and prevent pathological neovascularization in the retina.

Rearranging human germline segments builds combinatorial libraries that resolve the trade-off between antibody diversity and generation complexity.

Annulated dihydropyrimidines overcome weak antagonism by modifying the core structure to enhance binding affinity for pain treatment.

Encapsulating lipophilic drugs in 60-200 nm droplets bypasses the blood-brain barrier, enhancing bioavailability while reducing toxicity.

Cyclopentane prostaglandin analogs target FP receptors to lower intraocular pressure, overcoming the limited metabolic stability of natural eicosanoids.

Substituted fused tricyclic compounds block A2A receptors to relieve motor symptoms and provide neuroprotection without dopamine replacement side effects.

Synthesized collagen peptide fragments reduce VEGFA and IL-8 gene activity to prevent blue light-induced eye inflammation and visual decline.

Tocotrienol quinones protect optic nerve cells from mitochondrial dysfunction, slowing disease progression.

Grafting metformin and TAT peptide onto resveratrol-loaded PCL nanoparticles enhances retinal penetration to treat macular degeneration.

A glycosaminoglycan derivative composition regulates chemokine receptor activity through covalent complex formation.

Chlorotoxin agents inhibit angiogenesis by targeting pro-angiogenic factors, preventing tumor resistance through broad-spectrum inhibition.

A mouse IgE peptide vaccine induces anti-IgE antibodies that block mast cell binding.

Reducing molecular weight eliminates vascular permeability increasing activity, resolving safety issues without losing anti-inflammatory efficacy.

Self-delivering sd-rxRNA molecules bypass rigid structure barriers to achieve widespread distribution and uptake in all retinal cell layers.

Optimized alpha connexin peptide formulations with HPMC enhance stability and bioavailability to treat corneal injuries.

Diacylindazole derivatives inhibit hormone-sensitive and endothelial lipases to reduce free fatty acids and triglycerides in metabolic disorders.

Modified AAV capsids increase Müller cell infectivity, enabling robust gene delivery for treating ocular diseases.

Ripasudil promotes regulatory T cells to induce immune tolerance, resolving side effects from traditional immunosuppressants.

Liposomal curcumin combined with a calcium channel blocker prevents hemolysis and improves bioavailability for systemic disease treatment.

Activating c-myc and Notch pathways drives inner ear cell cycle reentry, overcoming transdifferentiation limits that deplete supporting cells.

Metabolic activation therapy stabilizes plasma glucose levels using programmable insulin pulses, reducing hypoglycemia risk during surgery.

Pichia extract microemulsions boost corneal mucin and hyaluronic acid production to resolve short residence time in dry eye treatments.

Metabolites from Streptococcus thermophilus replace chemical drugs to prevent UV damage while avoiding irritation.

Specific benzoimidazol-2-yl pyridine structures balance receptor potency with pharmaceutical properties to inhibit leukocyte recruitment.

Fusion proteins combine VEGFR1 and Tie2 domains to bind angiogenic ligands while resolving the trade-off between binding affinity and pharmacokinetic stability.

Merging IL-17 and IFN-gamma inhibition into one molecule resolves the trade-off between comprehensive treatment effectiveness and regimen simplicity.

Engineered hinge mutations lower anti-hinge antibody reactivity and viscosity, enabling higher concentration formulations.

Lactobacillus crispatus KBL693 strain inhibits histamine secretion to alleviate atopic dermatitis symptoms without drug-induced side effects.

TRIS and EDTA intermediaries prevent N-acetylcysteine degradation and odor, resolving storage instability while preserving biofilm disintegration.

A dual targeting antibody fuses a water-soluble ligand to the heavy or light chain N-terminus.

CDK2 inhibitors prevent cisplatin-induced ototoxicity despite unclear effectiveness in prior antioxidant studies.

Isoleucine substitution at position 3 resolves the trade-off between peptide truncation and C3 binding activity, extending half-life.

Segmenting receptor binding through D-amino acid stereochemistry yields selective kappa opioid agonists that minimize side effects.

Surface-modified particles penetrate mucus barriers, enabling efficient drug delivery and improved retention in ocular tissues.

A fetal support tissue composition suppresses epithelial cell proliferation and migration through biochemical inhibition.

Tricyclic compounds inhibit mGluR1 to treat chronic pain without affecting normal excitatory synaptic transmission.

Topomimetic calixarenes copy peptide surface characteristics to provide bactericidal activity without neurotoxicity.

Structural modifications to natural CYP metabolites improve chemical stability and bioavailability for treating neovascularization.

A SPINK2 mutant peptide inhibits human HTRA1 protease activity to preserve photoreceptor cells.

Selective FP receptor activation by the bicyclic compound lowers intraocular pressure while avoiding IP and EP1 side effects.

Replacing intracyclic oxygen with a difluorinated carbon creates stable analogues that resist enzymatic degradation while maintaining therapeutic efficacy.

Trametinib targets Erk and p38 kinases to resolve non-specific anti-inflammatory limitations in rosacea treatment.

A disposable mold with flow channels expels embedding material during compression to create thin hydrogel sections.